Novartis New Organizational Model

Value creation through growth and operational efficiencies Fully focused on topline growth (R&D, NTO not impacted; minimize disruption to frontline) Reducing complexity in organization above field force, reduce SG&A as % of sales to benchmarks ☑ USD ≥1bn SG&A annual savings by 2024 IM core margin mid-term high end of high 30s IM core margin mid- to long-term to reach low 40s 14 NOVARTIS NEW ORGANIZATIONAL MODEL | APRIL 04, 2022 | NOVARTIS INVESTOR PRESENTATION NOVARTIS | Reimagining Medicine

View entire presentation